06.27.17
Lonza today announced that it has received all regulatory approvals for the proposed acquisition of Capsugel S.A. With all final regulatory approvals in place, Lonza can now complete the transaction, which is expected to close in the next days subject to the satisfaction of customary closing conditions.
According to Lonza, following the closing of the Capsugel acquisition, Lonza will further strengthen its position as one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life.
Lonza Group AG In December, Lonza agreed to buy the US capsule maker from KKR & Co. for $5.5 billion, as the Swiss biotech and specialty chemicals company seeks to focus more on health care. The price includes refinancing of existing Capsugel debt of about $2 billion. The deal will be financed by a combination of debt and equity raising of as much as 3.3 billion francs ($3.2 billion). Lonza shares dropped as much as 7%.
According to Lonza, following the closing of the Capsugel acquisition, Lonza will further strengthen its position as one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life.
Lonza Group AG In December, Lonza agreed to buy the US capsule maker from KKR & Co. for $5.5 billion, as the Swiss biotech and specialty chemicals company seeks to focus more on health care. The price includes refinancing of existing Capsugel debt of about $2 billion. The deal will be financed by a combination of debt and equity raising of as much as 3.3 billion francs ($3.2 billion). Lonza shares dropped as much as 7%.
